|
|
Blood, 1 June 2005, Vol. 105, No. 11, pp. 4508-4515.
Prepublished online as a Blood First Edition Paper on February 10, 2005; DOI 10.1182/blood-2004-08-3238.
Previous Article | Table of Contents | Next Article 
NEOPLASIA
Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases
Mingjiang Xu,
Edward Bruno,
Joseph Chao,
Stephen Huang,
Guido Finazzi,
Steven M. Fruchtman,
Uday Popat,
Josef T. Prchal,
Giovanni Barosi,
Ronald Hoffman, for the MPD Research Consortium
From the Section of Hematology/Oncology, University of Illinois at Chicago Cancer Center, University of Illinois College of Medicine, Chicago, IL; the Department of Hematology, Ospedali Riuniti, Bergamo, Italy; the Mount Sinai School of Medicine, New York, NY; the Baylor College of Medicine, Houston, TX; The Instituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia, Italy.
Idiopathic myelofibrosis (IM) is characterized by increased numbers of CD34+ cells in the peripheral blood (PB). We explored the possible mechanisms underlying this abnormal trafficking of CD34+ cells. Plasma levels of neutrophil elastase (NE), total and active matrix metalloproteinase 9 (MMP-9), and soluble vascular cell adhesion molecule-1 (sVCAM-1) were dramatically increased in IM. The absolute number of CD34+ cells in the PB was correlated with the levels of sVCAM-1. Marked elevations of the levels of NE but not total and active MMP-9 as well as MMP-2 were detected in media conditioned by IM mononuclear cells (MNCs) as compared with that of healthy volunteers. IM MNC-conditioned media, however, was shown by zymographic analysis to contain increased gelatinolytic activity corresponding to the molecular weight of MMP-9. IM MNC-conditioned media also exhibited a greater ability to cleave VCAM-1 and c-kit in vitro, consistent with the biologic actions of NE. In addition, the increased ability of IM PB CD34+ cells to migrate through a reconstituted basement membrane was diminished by several inhibitors of MMP-9 activity, indicating that these cells express increased levels of this MMP. These data indicate that a proteolytic environment exists in IM which might result in the sustained mobilization of CD34+ cells.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. Y. Cho, J. Roboz, M. Xu, and R. Hoffman
Primary Myelofibrosis Is Associated with Truncation of the Plasma Chemokine SDF-1
Blood (ASH Annual Meeting Abstracts),
November 16, 2008;
112(11):
3731 - 3731.
[Abstract]
|
 |
|

|
 |

|
 |
 
O. Bock, J. Hoftmann, K. Theophile, K. Hussein, B. Wiese, J. Schlue, and H. Kreipe
Bone Morphogenetic Proteins Are Overexpressed in the Bone Marrow of Primary Myelofibrosis and Are Apparently Induced by Fibrogenic Cytokines
Am. J. Pathol.,
April 1, 2008;
172(4):
951 - 960.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. O. Ciurea, D. Merchant, N. Mahmud, T. Ishii, Y. Zhao, W. Hu, E. Bruno, G. Barosi, M. Xu, and R. Hoffman
Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis
Blood,
August 1, 2007;
110(3):
986 - 993.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Shi, Y. Zhao, T. Ishii, W. Hu, S. Sozer, W. Zhang, E. Bruno, V. Lindgren, M. Xu, and R. Hoffman
Effects of Chromatin-Modifying Agents on CD34+ Cells from Patients with Idiopathic Myelofibrosis
Cancer Res.,
July 1, 2007;
67(13):
6417 - 6424.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Hoffman and D. Rondelli
Biology and Treatment of Primary Myelofibrosis
Hematology,
January 1, 2007;
2007(1):
346 - 354.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Guglielmelli, R. Zini, C. Bogani, S. Salati, A. Pancrazzi, E. Bianchi, F. Mannelli, S. Ferrari, M.-C. Le Bousse-Kerdiles, A. Bosi, et al.
Molecular Profiling of CD34+ Cells in Idiopathic Myelofibrosis Identifies a Set of Disease-Associated Genes and Reveals the Clinical Significance of Wilms' Tumor Gene 1 (WT1)
Stem Cells,
January 1, 2007;
25(1):
165 - 173.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Bock, J. Neuse, K. Hussein, K. Brakensiek, G. Buesche, T. Buhr, B. Wiese, and H. Kreipe
Aberrant Collagenase Expression in Chronic Idiopathic Myelofibrosis Is Related to the Stage of Disease but Not to the JAK2 Mutation Status
Am. J. Pathol.,
August 1, 2006;
169(2):
471 - 481.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Hoffman and M. Xu
Is bone marrow fibrosis the real problem?
Blood,
May 1, 2006;
107(9):
3421 - 3422.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Passamonti, E. Rumi, D. Pietra, M. G. D. Porta, E. Boveri, C. Pascutto, L. Vanelli, L. Arcaini, S. Burcheri, L. Malcovati, et al.
Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders
Blood,
May 1, 2006;
107(9):
3676 - 3682.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U. Popat, A. Frost, E. Liu, Y. Guan, A. Durette, V. Reddy, and J. T. Prchal
High levels of circulating CD34 cells, dacrocytes, clonal hematopoiesis, and JAK2 mutation differentiate myelofibrosis with myeloid metaplasia from secondary myelofibrosis associated with pulmonary hypertension
Blood,
May 1, 2006;
107(9):
3486 - 3488.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. L. Levine and G. Wernig
Role of JAK-STAT Signaling in the Pathogenesis of Myeloproliferative Disorders
Hematology,
January 1, 2006;
2006(1):
233 - 239.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Tefferi
Pathogenesis of Myelofibrosis With Myeloid Metaplasia
J. Clin. Oncol.,
November 20, 2005;
23(33):
8520 - 8530.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Xu, E. Bruno, H. Ni, V. Rosti, M. Massa, G. Barosi, and R. Hoffman
SDF-1/CXCR4 Interactions in Idiopathic Myelofibrosis.
Blood (ASH Annual Meeting Abstracts),
November 16, 2005;
106(11):
3504 - 3504.
[Abstract]
|
 |
|

|
 |

|
 |
 
A. M. Vannucchi, A. Pancrazzi, P. Guglielmelli, S. Di Lollo, C. Bogani, G. Baroni, L. Bianchi, A. R. Migliaccio, A. Bosi, and F. Paoletti
Abnormalities of GATA-1 in Megakaryocytes from Patients with Idiopathic Myelofibrosis
Am. J. Pathol.,
September 1, 2005;
167(3):
849 - 858.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|